Publications by authors named "Murray Skinner"

Claim this Profile
T
The Minimal Clinically Important Difference in Allergen Immunotherapy: An Evidence-Based Approach.
Oliver Pfaar, Ralph Mösges, Michael S Blaiss, Sven Becker, Lawrence DuBuske, Murray A Skinner

Allergy· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Six Injections of Modified Adjuvanted PQ Grass Is Effective and Well-Tolerated in a Pivotal Phase III Trial.
Stefan Zielen, Jonathan A Bernstein, Gunter J Sturm, Marek Jutel, Oliver Pfaar, Murray A Skinner

Allergy· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Meta-Analysis of PQ Grass 27600 SU Efficacy and Quality of Life From Phase III Trials.
Stefan Zielen, Jonathan A Bernstein, Oliver Pfaar, Lawrence DuBuske, Ralph Mösges, Murray Skinner

Allergy· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modulation of Cellular, Molecular, and Humoral Responses by PQ Grass 27,600 SU for the Treatment of Seasonal Allergic Rhinitis: A Randomised Double Blind Placebo Control Exploratory Field Study.
Janice A Layhadi, Sviatlana Starchenka, Pieter-Jan De Kam, Elizabeth Palmer, Lily Y D Wu, Murray A Skinner

Allergy· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Ara h 2-expressing cucumber mosaic virus-like particle (VLP Peanut) induces in vitro tolerogenic cellular responses in peanut-allergic individuals.
Janice A Layhadi, Sviatlana Starchenka, Pieter-Jan De Kam, Elizabeth Palmer, Nandinee Patel, Murray A Skinner

J Allergy Clin Immunol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peripheral blood mononuclear cell transcriptome profile in a clinical trial with subcutaneous, grass pollen allergoid immunotherapy.
Sviatlana Starchenka, Kemi Oluwayi, Matthew Heath, Oliver Armfield, Mohamed Shamji, Murray Skinner

Clin Exp Allergy· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of antigen density and TLR ligands on preclinical efficacy of a VLP-based vaccine against peanut allergy.
Pascal S Krenger, Romano Josi, Jan Sobczak, Thalia L C Velazquez, Ina Balke, Murray A Skinner

Allergy· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The next generation virus-like particle platform for the treatment of peanut allergy.
Jan M Sobczak, Pascal S Krenger, Federico Storni, Mona O Mohsen, Ina Balke, Murray A Skinner

Allergy· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In situ delivery of nanoparticles formulated with micron-sized crystals protects from murine melanoma.
Mona O Mohsen, Matthew Heath, Matthias F Kramer, Thalia Carreno Velazquez, Alan Bullimore, Murray A Skinner

J Immunother Cancer· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunological effects of adjuvanted low-dose allergoid allergen-specific immunotherapy in experimental murine house dust mite allergy.
Alexander Heldner, Francesca Alessandrini, Dennis Russkamp, Sonja Heine, Benjamin Schnautz, Murray A Skinner

Allergy· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venom Immunotherapy: From Proteins to Product to Patient Protection.
Martin Feindor, Matthew D Heath, Simon J Hewings, Thalia L Carreno Velazquez, Simon Blank, Murray A Skinner

Toxins (Basel)· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dogmas, challenges, and promises in phase III allergen immunotherapy studies.
Pieter-Jan De Kam, Matthias F Kramer, Mohamed H Shamji, Kemi Oluwayi, Matthew D Heath, Murray A Skinner

World Allergy Organ J· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Shaping Modern Vaccines: Adjuvant Systems Using MicroCrystalline Tyrosine (MCT).
Matthew D Heath, Mona O Mohsen, Pieter-Jan de Kam, Thalia L Carreno Velazquez, Simon J Hewings, Murray A Skinner

Front Immunol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vaccine against peanut allergy based on engineered virus-like particles displaying single major peanut allergens.
Federico Storni, Andris Zeltins, Ina Balke, Matthew D Heath, Matthias F Kramer, Murray A Skinner

J Allergy Clin Immunol· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: -Derived E-DIII Protein Displayed on Immunologically Optimized VLPs Induces Neutralizing Antibodies without Causing Enhancement of Infection. 2019, , 72.
Gustavo Cabral-Miranda, Stephanie M Lim, Mona O Mohsen, Ilya V Pobelov, Elisa S Roesti, Murray A Skinner

Vaccines (Basel)· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety Evaluation of PQ Birch Allergy Immunotherapy to Support Product Development.
Paul Baldrick, James W Hutchings, Matthew D Heath, Murray A Skinner

Regul Toxicol Pharmacol· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transcriptome analysis and safety profile of the early-phase clinical response to an adjuvanted grass allergoid immunotherapy.
Sviatlana Starchenka, Matthew D Heath, Alyson Lineberry, Tim Higenbottam, Murray A Skinner

World Allergy Organ J· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New toxicity testing of PQ grass allergy immunotherapy to support product development.
Paul Baldrick, James W Hutchings, Matthew D Heath, Murray A Skinner, Tom Martin

J Appl Toxicol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
-
-Derived E-DIII Protein Displayed on Immunologically Optimized VLPs Induces Neutralizing Antibodies without Causing Enhancement of Infection.
Gustavo Cabral-Miranda, Stephanie M Lim, Mona O Mohsen, Ilya V Pobelov, Elisa S Roesti, Murray A Skinner

Vaccines (Basel)· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Vaccination with nanoparticles combined with micro-adjuvants protects against cancer.
Mona O Mohsen, Matthew D Heath, Gustavo Cabral-Miranda, Cyrill Lipp, Andris Zeltins, Murray A Skinner

J Immunother Cancer· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vaccination with nanoparticles combined with micro-adjuvants protects against cancer.
Mona O Mohsen, Matthew D Heath, Gustavo Cabral-Miranda, Cyrill Lipp, Andris Zeltins, Murray A Skinner

J Immunother Cancer· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Microcrystalline Tyrosine and Aluminum as Adjuvants in Allergen-Specific Immunotherapy Protect from IgE-Mediated Reactivity in Mouse Models and Act Independently of Inflammasome and TLR Signaling.
Deborah S Leuthard, Agathe Duda, Sandra N Freiberger, Sina Weiss, Isabella Dommann, Murray A Skinner

J Immunol· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Microcrystalline Tyrosine (MCT): A Depot Adjuvant in Licensed Allergy Immunotherapy Offers New Opportunities in Malaria.
Gustavo Cabral-Miranda, Matthew D Heath, Ariane C Gomes, Mona O Mohsen, Eduardo Montoya-Diaz, Murray A Skinner

Vaccines (Basel)· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical use of adjuvants in allergen-immunotherapy.
Ludger Klimek, Carsten B Schmidt-Weber, Matthias F Kramer, Murray A Skinner, Matthew D Heath

Expert Rev Clin Immunol· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Virus-Like Particle (VLP) Plus Microcrystalline Tyrosine (MCT) Adjuvants Enhance Vaccine Efficacy Improving T and B Cell Immunogenicity and Protection against Plasmodium berghei/vivax.
Gustavo Cabral-Miranda, Matthew D Heath, Mona O Mohsen, Ariane C Gomes, Paul Engeroff, Murray A Skinner

Vaccines (Basel)· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis